Laidi Charles, Bouaziz Noomane, Haffen Emmanuel, Domenech Philippe, Duchesnay Edouard, Favre Pauline, Fakra Éric, Houenou Josselin, Iftimovici Anton, Lefrere Antoine, Polosan Mircea, Sescousse Guillaume, Sauvaget Anne, Jardri Renaud
Université Paris Est Créteil, Institut Mondor de la Recherche Biomédicale, Assistance Publique des Hôpitaux de Paris, France - Fondation FondaMental, France - Université Paris-Saclay, Neurospin, CEA, UNIACT Lab, PsyBrain Team, F-91191 Gif-sur-Yvette, France.
Fondation FondaMental, France - Unité de Neuromodulation, Pôle Universitaire 93G03, EPS Ville Evrard, Neuilly-sur-Marne, France.
Med Sci (Paris). 2025 May;41(5):500-507. doi: 10.1051/medsci/2025061. Epub 2025 May 26.
Magnetic resonance imaging (MRI) can be used to investigate the neurobiological basis of psychiatric disorders such as schizophrenia, bipolar disorders, autism spectrum disorders and resistant depression. Although differences in cortical thickness between patients and controls have been well demonstrated, there is currently no valid MRI-based biomarker for psychiatric disorders. The challenge of precision psychiatry is to develop biomarkers, that are specific for a given pathology or clinical dimension, but also capable of predicting clinical evolution or response to treatment, to transform patient management. Functional magnetic resonance imaging could also be a promising tool for the individualized targeting of non-invasive neuromodulation in depression or resistant hallucinations, as well as for functional magnetic resonance imaging-based neurofeedback.